

### **Succession of Manufacturing and Marketing Approval for Three Products from Mitsubishi Tanabe Pharma**

Fuji Pharma Co., Ltd. (hereinafter referred to as “Fuji”) has announced that Fuji entered into an agreement to succeed the manufacturing and marketing approval and marketing rights, etc. of three products “AZANIN<sup>®</sup> Tablets 50mg”, “CHOLEBINE<sup>®</sup> Tablets 500mg /CHOLEBINE<sup>®</sup> Mini 83%” and “SURFACTEN<sup>®</sup> 120mg” from Mitsubishi Tanabe Pharma Corporation (Head office: Osaka, Japan, hereinafter referred to as “MTPC”) on 29th January.

These three products are playing an important role in providing treatment option by MTPC, a member of Mitsubishi Chemical Group.

Fuji will succeed manufacturing and marketing approval, and marketing rights, etc. for three products sequentially in 4Q/FY2024 (Jul.-Sep. 2024) and thereafter.

AZANIN<sup>®</sup> is an immunosuppressant used to treat organ transplant rejection, Crohn’s disease, ulcerative colitis and rheumatic diseases. CHOLEBINE<sup>®</sup> is used to treat hypercholesterolemia, can be used during pregnancy and lactation. SURFACTEN<sup>®</sup> is used to treat new born respiratory distress syndrome. CHOLEBINE<sup>®</sup> and SURFACTEN<sup>®</sup> are products of perinatal medical. These are closely related to Fuji’s existing business areas such as women’s healthcare and gastroenterology.

After the succession, Fuji will promote the proper use of medicines and ensure their stable supply to support patients’ healthy lives.

In addition, the impact of this succession on FY9/2024 consolidated earnings forecast is insignificant.

< Three products that Fuji will succeed the manufacturing and marketing approval >

	Product name	Therapeutic category
1	AZANIN <sup>®</sup> Tablets 50mg	Immunosuppressant
2	CHOLEBINE <sup>®</sup> Tablets 500mg/ CHOLEBINE <sup>®</sup> Mini83%	Hypercholesterolemia
3	SURFACTEN <sup>®</sup> 120mg	Newborn respiratory distress syndrome

---

**[About Mitsubishi Tanabe Pharma Corporation]**

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy, "Forging the future". MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis.

For more information, go to <https://www.mt-pharma.co.jp/e/>

**Note**

The financial forecasts and other projections provided in this release are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks. Actual results may differ significantly from these forecasts for a number of reasons. It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification. Information in this release about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

---

**For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsks@fujipharma.jp](mailto:fsks@fujipharma.jp)